South Korea-based AI drug discovery and development firm SyntekaBio has introduced its new Develop Now, Pay Later initiative, a drug discovery model that allows pharmaceutical and biotechnology companies to test the validity of a target protein of interest.
The service aims to reduce risk for drug developers by enabling them to conduct a complimentary feasibility study to determine the project's viability. Upon confirmation, Syntekabio will employ its STB LaunchPad program, powered by its proprietary AI-driven DeepMatcher technology platform, to generate optimized leads and IND-enabled candidates. The client will make payments once the validated results are provided.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.